KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Liabilities (2016 - 2026)

Moderna (MRNA) has disclosed Total Liabilities for 11 consecutive years, with $4.1 billion as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities rose 54.66% year-over-year to $4.1 billion; the TTM value through Mar 2026 reached $4.1 billion, up 54.66%, while the annual FY2025 figure was $3.7 billion, 13.79% up from the prior year.
  • Total Liabilities hit $4.1 billion in Q1 2026 for Moderna, up from $3.7 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $10.5 billion in Q1 2022 and bottomed at $2.6 billion in Q2 2025.
  • Average Total Liabilities over 5 years is $5.0 billion, with a median of $4.1 billion recorded in 2026.
  • Year-over-year, Total Liabilities crashed 50.05% in 2023 and then soared 54.66% in 2026.
  • Moderna's Total Liabilities stood at $6.7 billion in 2022, then plummeted by 32.12% to $4.6 billion in 2023, then decreased by 29.11% to $3.2 billion in 2024, then rose by 13.79% to $3.7 billion in 2025, then rose by 10.63% to $4.1 billion in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $4.1 billion, $3.7 billion, and $2.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.